Tony Mok, MD

Articles

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Future Perspectives in EGFR+ NSCLC

February 14th 2022

Global perspectives on the future management of EGFR+ non–small cell lung cancer given recent advances in the treatment paradigm.

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

February 14th 2022

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: Small Cell Transformation and MET Amplification

February 7th 2022

Panelists consider optimal second-line therapy for patients who acquired resistance to frontline TKIs in EGFR+ advanced NSCLC.

EGFR+ Advanced NSCLC: Molecular Testing in Patients Resistant to Frontline TKIs

February 7th 2022

Following treatment failure on frontline TKIs in EGFR+ advanced NSCLC, experts consider biomarker testing to inform second-line treatment.

EGFR+ Advanced NSCLC: Review of Bevacizumab-Based Combination Therapy

January 31st 2022

Experts review frontline combination approaches with bevacizumab in EGFR+ advanced non–small cell lung cancer.

Regional Approaches to Frontline Treatment for EGFR+ Advanced NSCLC

January 31st 2022

A comprehensive discussion on frontline treatment options for patients with EGFR+ advanced non–small cell lung cancer.

Resectable NSCLC: Is There a Role for Multidisciplinary Care and Neoadjuvant Therapy?

January 24th 2022

Closing out their discussion on resectable NSCLC, experts review multidisciplinary care strategies and the role of neoadjuvant therapy in patients identified for resection.

Global Perspectives on Routine Molecular Testing in Postoperative NSCLC

January 24th 2022

In light of evolving treatment options for resectable non–small cell lung cancer, panelists discuss biomarker testing to guide adjuvant therapy in the postoperative setting.

Is There a Continued Role for First-Generation TKIs in Resectable NSCLC?

January 17th 2022

Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.

The ADAURA Trial: Adjuvant Osimertinib in EGFR+ Resectable NSCLC

January 17th 2022

Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.

Is There a Role for Postoperative Radiotherapy in Stage III NSCLC?

January 12th 2022

A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.

Treatment Strategies for Resectable NSCLC in Asia, With a Focus on Stage IB Disease

January 12th 2022

Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.

Biomarkers for Guiding Treatment in NSCLC: Liquid Biopsy Versus Tissue-Based Testing

January 7th 2022

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

How Has Biomarker Testing Impacted Clinical Practice Across Geographic Regions?

January 4th 2022

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Considerations for Biomarker Testing in NSCLC: Gene Panel Size and Reimbursement

December 22nd 2021

Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.

Regional Recommendations and Approaches to Biomarker Testing in NSCLC

December 22nd 2021

Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.

Dr. Mok Discusses Updated Data With Pembrolizumab in NSCLC

April 25th 2019

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC

August 5th 2016

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.